Haystack MRD
Tumor-informed ctDNA molecular residual disease assay for solid tumors using WES-derived personalized panels tracking up to 50 variants.
- Developer
- Quest Diagnostics
- Intended use
- Mrd
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- Haystack MRD current Quest configuration (2026)
- Evidence context
- 1 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.